Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

Launched by SUN YAT-SEN UNIVERSITY · May 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment approach for women with stage IIIC cervical cancer, which is a more advanced form of this disease. The trial compares two treatment plans: one group will receive neoadjuvant chemotherapy (which is treatment given before surgery) using specific drugs called albumin-bound paclitaxel and carboplatin, followed by chemoradiation therapy (a combination of chemotherapy and radiation). The other group will go straight to chemoradiation without the initial chemotherapy. The goal is to see which approach is more effective and safer for patients.

To participate in this trial, women must be between 18 and 70 years old and have a confirmed diagnosis of cervical cancer that meets certain criteria, including having a tumor larger than 4 cm or lymph nodes larger than 2 cm. Participants can expect to receive close monitoring and care throughout the trial, and they will be contributing to important research that could help improve treatment options for cervical cancer in the future. If you or someone you know is considering joining, it’s important to discuss this with a healthcare provider to understand the potential benefits and risks.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. pathologically comfirmed : squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix；
• • 2. FIGO (2018 International Federation of Gynecology and Obstetrics) stage IIIC with carcinoma \>4 cm in greatest dimension and/or lymph node \>2 cm in short axis at initial diagnosis.
• • 3. age 18 to 70 years；
• • 4. Eastern Cooperative Oncology Group performance status 0 to 2；
• • 5. adequate organ function.
• Exclusion Criteria:
• • 1. not at initial diagnosis; 2. with other kind of tumor.
• • -